drugset / Trial / NCT03679975
Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)
Phase 2
Terminated
9 enrolled
Aquestive Therapeutics
Covance · collabinVentiv Health Clinical · collab
NaSingle-groupOpen-labelOther
Summary
The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.
Timeline
- Start
- 2018-04-04
- Primary completion
- 2018-09-26
- Completion
- 2018-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Riluzole | Small molecule | 50 mg | Other |